...
首页> 外文期刊>ACS nano >Charge-Convertible Carbon Dots for Imaging Guided Drug Delivery with Enhanced in Vivo Cancer Therapeutic Efficiency
【24h】

Charge-Convertible Carbon Dots for Imaging Guided Drug Delivery with Enhanced in Vivo Cancer Therapeutic Efficiency

机译:电荷可转换碳点用于成像指导药物递送,具有增强的体内癌症治疗效率

获取原文
获取原文并翻译 | 示例
           

摘要

Carbon dots (CDs) are remarkable nanocarriers due to their promising optical and biocompatible capabilities. However, their practical applicability in cancer therapeutics is limited by their insensitive surface properties to complicated tumor microenvironment in vivo. Herein, a tumor extracellular microenvironment-responsive drug nanocarrier based on cisplatin(IV) prodrug-loaded charge convertible CDs (CDs-Pt(IV)@PEG-(PAH/DMMA)) was developed for imaging-guided drug delivery. An anionic polymer with dimethylmaleic acid (PEG-(PAH/DMMA)) on the fabricated CDs-Pt(IV)@PEG-(PAH/DMMA) could undergo intriguing charge conversion to a cationic polymer in mildly acidic tumor extracellular microenvironment (pH similar to 6.8), leading to strong electrostatic repulsion and release of positive CDs-Pt(IV). Importantly, positively charged nanocarrier displays high affinity to negatively charged cancer cell membrane, which results in enhanced internalization and effective activation of cisplatin(IV) prodrug in the reductive cytosol. The in vitro experimental results confirmed that this promising charge-convertible nanocarrier possesses better therapeutic efficiency under tumor extracellular microenvironment than normal physiological condition and noncharge-convertible nanocarrier. The in vivo experiments further demonstrated high tumor-inhibition efficacy and low side effects of the charge-convertible CDs, proving its capability as a smart drug nanocarrier with enhanced therapeutic effects. The present work provides a strategy to promote potential clinical application of CDs in the cancer treatment.
机译:碳点(CD)由于其有希望的光学和生物相容性能力而成为出色的纳米载体。然而,它们在癌症治疗中的实际适用性受限于其对体内复杂的肿瘤微环境不敏感的表面性质。在这里,肿瘤细胞外微环境响应药物纳米载体的基础上,载有顺铂(IV)前药的电荷可转换CD(CDs-Pt(IV)@ PEG-(PAH / DMMA))用于成像引导的药物递送。制备的CD-Pt(IV)@ PEG-(PAH / DMMA)上带有二甲基马来酸(PEG-(PAH / DMMA))的阴离子聚合物可能会在中等酸性的肿瘤细胞外微环境(pH值相似)中发生有趣的电荷转化为阳离子聚合物至6.8),导致强烈的静电排斥并释放出正CD-Pt(IV)。重要的是,带正电的纳米载体对带负电的癌细胞膜显示出高亲和力,从而导致还原性胞质溶胶中的顺铂(IV)前药增强的内在化和有效活化。体外实验结果证实,这种有希望的电荷可转换纳米载体在肿瘤细胞微环境下比正常生理条件和不可电荷转换的纳米载体具有更好的治疗效果。体内实验进一步证明了可电荷转换CD的高肿瘤抑制功效和低副作用,证明了其作为具有增强治疗效果的智能药物纳米载体的能力。本工作提供了一种策略来促进CD在癌症治疗中的潜在临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号